Gubra (One-pager): Investors discounts higher likelihood of success of its obesity focused pipeline.
Following the release of its annual report for 2023 last week, investors looking for underappreciated obesity assets has sent Gubra shares soaring and yesterday the Gubra stock got another big boost as Novo Nordisk at their Capital Markets Day resented early data from obesity related developing projects that were comparable to those of Gubra. The Gubra stock was up 13 percent yesterday, almost 50 percent since the release of the annual report last week and has doubled since the start of the year.
As we have written repeatedly, Gubra’s obesity focused pipeline seem to have been underappreciated by the market for a long time, but now investor awareness of the pipeline’s depth and breadth within obesity is quickly building. At the Capital Markets Day, Novo Nordisk among other things presented amylin analog weight loss data which received a lot of attention, and which were also comparable to those of Gubra’s amylin analog, GUBamy. As an example, in combination with Novo Nordisk’s semaglutide, GUBamy has shown weight loss of almost 20 percent after 28 days in pre-clinical study and are currently enrolling patients to a Phase 1 study in UK.
Following the report and the huge share price increase, we have revisited our company guided DCF-model and updated our One-Pager accordingly. As can be seen, the market increasingly discounts a successful development, approval and subsequent launch and commercialization of products from Gubra’s pipeline, thereby showing high and increasing confidence in Gubra’s prospects.
Disclaimer: HC Andersen Capital receives payment from Gubra for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 08:50 AM 08-03-2024.
Gubra
Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar.. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.
Read more on company page